Skip to content
Oncology Research Hub

Richmond, Virginia

Cancer clinical trials in Richmond, VA

135 cancer studies are recruiting participants at sites in Richmond as of November 16, 2026, according to ClinicalTrials.gov. Oncology Research Hub can help you understand your options and connect with a study team.

Call (888) 343-1186
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Richmond at a glance

  • 135 studies are recruiting at a site in Richmond.
  • By phase: Phase 1 (5), Phase 1/2 (10), Phase 2 (32), Phase 2/3 (6), Phase 3 (63), Phase 4 (1), No phase (8), Observational (10). Studies of devices and behavioral approaches have no phase.
  • By sponsor: university, hospital or other (65), industry (47), government (23).
  • By research area: Lymphoma (37), Breast Cancer (34), Lung Cancer (31), Prostate Cancer (16), Melanoma (11), Pancreatic Cancer (6).
  • Most recent update to one of these records: November 16, 2026.

Breast cancer studies recruiting in Richmond

Basic details from each study's public record (the 30 most recently updated of 135). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    VCU Massey Comprehensive Cancer Center
    Registry record
    NCT03606967 · updated
  2. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    • Phase 2
    • All ages
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Henrico Doctor's Hospital · VCU Massey Cancer Center at Stony Point · VCU Massey Comprehensive Cancer Center
    Registry record
    NCT05564377 · updated
  3. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Bon Secours Saint Mary's Hospital · VCU Massey Cancer Center at Stony Point · VCU Massey Comprehensive Cancer Center
    Registry record
    NCT06058377 · updated
  4. A Study to Learn How Well Participants With a Specific Type of Early Breast Cancer (ER-Positive, HER2-Negative) Tolerate and Stay on Treatment With Giredestrant and How They Feel During Treatment

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Virginia Cancer Institute
    Registry record
    NCT07827573 · updated
  5. The Vanguard Study: Testing a New Way to Screen for Cancer

    • No phase
    • Ages 45 to 75
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    VCU Massey Cancer Center at Stony Point · VCU Massey Comprehensive Cancer Center
    Registry record
    NCT06995898 · updated
  6. Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Bon Secours Richmond Community Hospital · Bon Secours Saint Mary's Hospital · VCU Massey Comprehensive Cancer Center
    Registry record
    NCT07391774 · updated
  7. Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Virginia Cancer Institute ( Site 0034)
    Registry record
    NCT06393374 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Richmond, VA on ClinicalTrials.gov.

Lung cancer studies recruiting in Richmond

  1. Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    VCU Massey Comprehensive Cancer Center
    Registry record
    NCT06287775 · updated
  2. A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    Virginia Commonwealth University
    Registry record
    NCT07063745 · updated
  3. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    VCU Massey Cancer Center at Stony Point · VCU Massey Comprehensive Cancer Center · Virginia Cancer Institute
    Registry record
    NCT04267848 · updated
  4. Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

    • Phase 3
    • Ages 70 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    VCU Massey Cancer Center at Stony Point · VCU Massey Comprehensive Cancer Center
    Registry record
    NCT06096844 · updated
  5. Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Virginia Cancer Institute
    Registry record
    NCT06498635 · updated
  6. Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    Virginia Commonwealth University (Vcu)
    Registry record
    NCT07100080 · updated
  7. A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    VCU Health Adult Outpatient Pavillion ( Site 0193)
    Registry record
    NCT06623422 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Richmond, VA on ClinicalTrials.gov.

Prostate cancer studies recruiting in Richmond

  1. Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Study site
    VCU Massey Comprehensive Cancer Center
    Registry record
    NCT04423211 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Richmond, VA on ClinicalTrials.gov.

Melanoma studies recruiting in Richmond

  1. Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma

    • Phase 3
    • Ages 75 and older
    • All sexes
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Study sites
    VCU Massey Cancer Center at Stony Point · VCU Massey Comprehensive Cancer Center
    Registry record
    NCT07068074 · updated
  2. BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    VCU Massey Cancer Center at Stony Point · VCU Massey Comprehensive Cancer Center · Virginia Cancer Institute
    Registry record
    NCT05136196 · updated
  3. A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Regeneron Pharmaceuticals
    Study site
    Virginia Commonwealth University Massey Cancer Center
    Registry record
    NCT06246916 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Richmond, VA on ClinicalTrials.gov.

Lymphoma studies recruiting in Richmond

  1. Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eastern Cooperative Oncology Group
    Study site
    VCU Massey Comprehensive Cancer Center
    Registry record
    NCT06724237 · updated
  2. A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Virginia Cancer Institute ( Site 0148)
    Registry record
    NCT06717347 · updated
  3. A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    VCU Health Adult Outpatient Pavillion ( Site 0138)
    Registry record
    NCT06890884 · updated
  4. Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    VCU Massey Comprehensive Cancer Center
    Registry record
    NCT03739814 · updated
  5. Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    VCU Massey Cancer Center at Stony Point · VCU Massey Comprehensive Cancer Center
    Registry record
    NCT04269902 · updated
  6. Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    VCU Massey Comprehensive Cancer Center
    Registry record
    NCT04301076 · updated
  7. A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • Ages 1 to 30
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    VCU Massey Comprehensive Cancer Center
    Registry record
    NCT04546399 · updated
  8. Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    VCU Massey Comprehensive Cancer Center
    Registry record
    NCT04840602 · updated
  9. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    VCU Massey Comprehensive Cancer Center
    Registry record
    NCT05675410 · updated
  10. Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    VCU Massey Cancer Center at Stony Point · VCU Massey Comprehensive Cancer Center
    Registry record
    NCT06337318 · updated
  11. Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    VCU Massey Comprehensive Cancer Center
    Registry record
    NCT06649812 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Richmond, VA on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Richmond

  1. Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study sites
    VCU Massey Cancer Center at Stony Point · VCU Massey Comprehensive Cancer Center
    Registry record
    NCT06807437 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Richmond, VA on ClinicalTrials.gov.

Ask about studies near Richmond

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Virginia

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Oncology Research Hub does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-1186

or send a short form

How should we reach you?

Call